Schroder Investment Management Group boosted its position in shares of Chemed Co. (NYSE:CHE - Free Report) by 1.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 45,291 shares of the company's stock after acquiring an additional 463 shares during the period. Schroder Investment Management Group owned 0.30% of Chemed worth $23,906,000 at the end of the most recent quarter.
Several other large investors have also added to or reduced their stakes in the company. Raymond James Financial Inc. bought a new stake in shares of Chemed during the 4th quarter valued at $42,023,000. HighTower Advisors LLC grew its position in shares of Chemed by 78.0% during the third quarter. HighTower Advisors LLC now owns 3,730 shares of the company's stock worth $2,246,000 after purchasing an additional 1,634 shares in the last quarter. XTX Topco Ltd raised its stake in Chemed by 111.5% during the 3rd quarter. XTX Topco Ltd now owns 2,843 shares of the company's stock valued at $1,709,000 after purchasing an additional 1,499 shares during the period. Geode Capital Management LLC lifted its holdings in Chemed by 4.9% in the 3rd quarter. Geode Capital Management LLC now owns 335,443 shares of the company's stock worth $201,820,000 after purchasing an additional 15,791 shares in the last quarter. Finally, Signal Advisors Wealth LLC boosted its stake in Chemed by 60.7% in the 4th quarter. Signal Advisors Wealth LLC now owns 4,995 shares of the company's stock worth $2,647,000 after purchasing an additional 1,886 shares during the period. Hedge funds and other institutional investors own 95.85% of the company's stock.
Insider Transactions at Chemed
In other Chemed news, CEO Kevin J. Mcnamara sold 2,000 shares of the business's stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $593.67, for a total transaction of $1,187,340.00. Following the transaction, the chief executive officer now owns 102,679 shares in the company, valued at $60,957,441.93. The trade was a 1.91 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 3.32% of the company's stock.
Chemed Price Performance
Shares of Chemed stock traded down $22.01 during trading hours on Monday, reaching $575.33. The company's stock had a trading volume of 162,812 shares, compared to its average volume of 96,001. The firm has a 50 day moving average price of $580.26 and a 200-day moving average price of $567.90. The stock has a market cap of $8.42 billion, a P/E ratio of 29.07, a P/E/G ratio of 2.15 and a beta of 0.49. Chemed Co. has a one year low of $512.12 and a one year high of $632.22.
Chemed Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Friday, March 14th. Shareholders of record on Monday, February 24th were given a dividend of $0.50 per share. The ex-dividend date of this dividend was Monday, February 24th. This represents a $2.00 dividend on an annualized basis and a yield of 0.35%. Chemed's dividend payout ratio (DPR) is presently 10.05%.
Analyst Ratings Changes
CHE has been the subject of several research analyst reports. StockNews.com raised shares of Chemed from a "hold" rating to a "buy" rating in a research note on Friday, March 7th. Royal Bank of Canada increased their price objective on shares of Chemed from $633.00 to $667.00 and gave the company an "outperform" rating in a report on Friday, March 14th.
Check Out Our Latest Report on CHE
Chemed Profile
(
Free Report)
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.
Further Reading

Before you consider Chemed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemed wasn't on the list.
While Chemed currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.